Incyte

United Therapeutics

Gilead Sciences

Natera

Alnylam Pharmaceuticals

Neurocrine Biosciences

Vertex Pharmaceuticals

Amgen

Insmed

Sarepta Therapeutics

SPDR S&P Biotech ETF

XBI tracks an equal-weighted index of US biotechnology stocks.

iShares Nasdaq Biotechnology ETF

Initial public offerings by small private biotech companies are poised to stage a comeback later in 2023 as the pace of interest rate hikes slows, but tougher economic conditions will make investors more inclined to pick firms which have drugs in human trials.

Analysis: Biotech IPOs to bloom with spotlight on startups with human trial data

ROBO Global Robotics and Automation ETF

Simplifying your investment strategy can help minimize your risk while still allowing you to earn some great returns.

2 ETFs That Can Set You Up for Life

Pharma and biotech stocks moved in opposite directions last year, but fortunes are shifting.

Why Biotech Is Poised for a Recovery This Year

Catalyst Pharmaceuticals

Prometheus Biosciences

SAGE Therapeutics

In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.

Biotech's Blockbuster Week: 3 Stocks to Watch

SPDR S&P Pharmaceuticals ETF

A handful of acquisitions this week point to a more deal-friendly year for biopharma and biotech companies, though none has generated the kind of excitement seen in years past.

Will 2023 be the year that pharma M&A makes a comeback?

Global X Longevity Thematic ETF 

ARK Genomic Revolution Multi-Sector ETF

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

BlackRock Future Health ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

Global X Telemedicine & Digital Health ETF

First Trust NYSE Arca Biotechnology Index Fund

Fidelity MSCI Health Care ETF

First Trust Nasdaq Pharmaceuticals ETF 

First Trust Health Care AlphaDEX Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

 Franklin Genomic Advancements ETF

ROBO Global Healthcare Technology and Innovation ETF

Invesco Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare Providers ETF

iShares U.S. Medical Devices ETF

iShares Global Healthcare ETF

iShares U.S. Healthcare ETF

Eli Lilly

Global X Longevity Thematic ETF

First Trust Indxx Medical Devices ETF

Merck

Novo Nordisk

Invesco Dynamic Biotechnology & Genome ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Simplify Health Care ETF

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

Invesco S&P SmallCap Health Care ETF

Invesco DWA Healthcare Momentum ETF

Invesco S&P 500 Equal Weight Health Care ETF

ALPS Medical Breakthroughs ETF

Vanguard Health Care ETF

Wisdomtree BioRevolution Fund

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

Health Care Select Sector SPDR Fund

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

Can Health Care Stocks Outperform Again In 2023?

Vanguard Long-Term Bond ETF

Vanguard Small Cap Value ETF

These ETFs could be big winners in the new year.

3 Unstoppable ETFs to Stock Up On in 2023

Global X SuperDividend US ETF

SPDR S&P 500 ETF Trust

SPDR Portfolio S&P 500 High Dividend ETF

SPDR S&P Oil & Gas Exploration & Production ETF

The S&P 500 just finished its worst year since 2008. What Lies ahead for 2023?

ETFs to Buy for 2023 After S&P 500's Worst Year Since 2008

If there's one biotech area to watch in 2023, it's genetic medicine, like CRISPR. But other trends also point to a big year for biotech stocks.

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks

WisdomTree U.S. Earnings 500 Fund

iShares MSCI United Kingdom ETF

SPDR Portfolio S&P 500 Value ETF

iShares 0-5 Year TIPS Bond ETF

Vanguard FTSE Europe ETF

Wall Street had a shaky start to 2023 after the S&P 500's worst year since 2008. For Investors, we thus have jotted down a few predictions for 2023.

6 ETF Predictions for 2023

Amazon

Brookfield Infrastructure Partners L.P.

Netflix

Vanguard S&P 500 ETF

Now is the time to begin crafting your watch list for 2023.

5 Top Stocks for January

The biotech sector has been outperforming the major U.S. indices for the past few months. Can the strength continue?

Biotech is Set for a Blockbuster 2023: Here's Why

Valuations on biotechnology stocks have moderated substantially since the pandemic peak in 2021, with the SPDR S&P Biotech ETF erasing more than 5 years' worth of gains since 2018. We think XBI presents attractive growth at a reasonable price, with the expectation that biotech revenues should be able to sustain a healthy 7% CAGR over the next 5 years.

XBI: Attractive Value In Diversified Biotech Growth

AbbVie

Altimmune

Ardelyx

Axsome Therapeutics

ProShares Ultra Nasdaq Biotechnology

Krystal Biotech

Some of the hottest biotech stocks are safe and recession-proof. After all, we can't stop people from aging – at least, not yet.

The 7 Hottest Biotech Stocks to Own in 2023 and Beyond

ProShares UltraPro QQQ

This article explains how we use the ProShares UltraPro QQQ ETF and SPDR S&P Biotech ETF in our aggressive growth portfolio (“AGP”). The key is to stay disciplined, and we follow two simple rules: the volatility index and the valuation.

TQQQ And XBI: Boosters For My 2023 Growth

The drug-price reform focus of Congress affects biopharma stock prices. The likelihood that Republicans will control at least the House, is good for biotech stocks.

XBI: Mid-Term Election Results Are Good For Biotech Stocks

Biotech earnings have come in upbeat in the third quarter.

How Are Biotech ETFs Reacting to Q3 Earnings Releases?

Today, we take a look at the SPDR S&P Biotech ETF, a widely diversified ETF comprised of myriad small and midcap biotech stocks. This ETF appears to be set up to outperform in the quarters ahead for several reasons after losing approximately half of its value since the start of 2021.

Biotech And XBI: The Bottom Is In

Biotech will continue to outperform the benchmark since the U.S. economy is currently in late-cycle expansion, says Bryn Talkington. She's a Managing Partner at Requisite Capital Management.

XBI vs IBB: what's a better way to play the biotech space?

XBI is down 26% since January and down 33% since the same time last year following a correction fueled by pandemic-era investment. This year's drawdown of XBI provides opportunity for gains due to fundamental makeup, technical signals, and catalyst potential.

XBI: A Classic 'Glass Half Full Or Half Empty' Story

Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund.

This Beaten-Down ETF Is Still a Screaming Bear-Market Buy

First Trust Financials AlphaDEX Fund

Invesco S&P 500 Enhanced Value ETF

SPDR S&P Retail ETF

The current pullback in the S&P 500 is now the longest from peak to trough since the March 2009 low at 269 days and counting, according to research from Compound Capital Advisors, as quoted on Yahoo Finance. Stocks may be up for a bear-market rally.

Bear Market Rally in the Cards? Top-Ranked Low P/E ETFs to Tap

Akero Therapeutics Inc

Biogen

bluebird bio

Chemocentryx

Forma Therapeutics Holdings

Karuna Therapeutics Inc

Pfizer

Rhythm Pharmaceuticals

Biotechs are relatively better positioned in this fourth quarter compared to the broader market. Path of interest rates is clearer for 2022 and the Fed is closer to a pause early next year as it calibrates down its response from a hammer approach.

Biotech Stocks Well-Positioned For Fourth Quarter

Credit Suisse

AdvisorShares Pure US Cannabis ETF

Now's not the best time to bet the farm on anything other than more uncertainty coming up.

My 3 Biggest Stock Market Predictions for October

Proshares S&P Kensho Cleantech ETF

iShares North American Tech-Multimedia Networking ETF

Invesco DB US Dollar Index Bullish Fund

Consumer Discretionary Select Sector SPDR Fund

After logging the best month since July 2020, the Wall Street rally fizzled in August on aggressive Fed rate hike speculation. This has pushed the major indices to end the quarter with losses.

Top-Ranked ETFs That Beat the Market in Q3

News for SPDR S&P Biotech ETF ETF (XBI)